Skip to search formSkip to main contentSkip to account menu

Truvada

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Background. Hepatitis B virus (HBV) and human immunodeficiency virus (HIV) coinfection has emerged as an important cause of… 
Highly Cited
2015
Highly Cited
2015
Once-daily Truvada (Emtricitabine/Tenofovir) as a method of pre-exposure prophylaxis (PrEP) is one of the most promising… 
Highly Cited
2012
Highly Cited
2012
Background Daily pre-exposure prophylaxis (PrEP) with Truvada (a combination of emtricitabine (FTC) and tenofovir (TFV… 
2012
2012
Background: Highly active antiretroviral therapy (HAART) has reduced the morbidity associated with HIV infection, and prolonged… 
2011
2011
ABSTRACT Daily preexposure prophylaxis (PrEP) with Truvada (emtricitabine [FTC] and tenofovir disoproxil fumarate [TDF]) is a… 
2011
2011
Background: Combination emtricitabine (FTC) or lamivudine (LAM) with tenofovir disoproxil (TDF) is the recommended first-line… 
Highly Cited
2010
Highly Cited
2010
Treating monkeys with single doses of an antiretroviral drug before and after exposure to SHIV provides protection against… 
2008
2008
The objective was to evaluate the effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to Truvada® (TVD…